TGTX— TG THERAPEUTICS, INC.

MaterialsBiotechnology$7.5B mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Revenue	$616.3M+87.3%	$329.0M+40.8%	$233.7M+8290.0%	$2.8M
Cost of revenue	$100.7M+161.7%	$38.5M+172.4%	$14.1M+5232.5%	$265K
Noncash compensation	$16.6M+48.9%	$11.2M-14.2%	$13.0M-1.6%	$13.2M
Other research and development	$143.6M+72.7%	$83.1M+31.6%	$63.2M-43.7%	$112.1M
Total research and development	$160.2M+69.9%	$94.3M+23.8%	$76.2M-39.2%	$125.4M
Noncash compensation	$48.1M+53.1%	$31.4M+25.9%	$24.9M+318.1%	$6.0M
Other selling, general and administrative	$184.0M+49.7%	$122.9M+25.7%	$97.8M+52.7%	$64.0M
Total selling, general and administrative	$232.0M+50.4%	$154.3M+25.7%	$122.7M+75.3%	$70.0M
Total costs and expenses	$493.0M+71.7%	$287.1M+34.8%	$213.0M+8.9%	$195.6M
Operating income	$123.3M+194.1%	$41.9M+103.2%	$20.6M+110.7%	-$192.8M
Interest expense	$26.7M+11.2%	$24.0M+90.5%	$12.6M+23.8%	$10.2M
Other income	-$10.8M-40.3%	-$7.7M-52.5%	-$5.0M-7.4%	-$4.7M
Total other expense	$15.9M-2.5%	$16.3M+115.8%	$7.6M+37.8%	$5.5M
Net income before taxes	$107.4M+319.6%	$25.6M+95.9%	$13.1M+106.6%	-$198.3M
Income tax benefit (expense)	$339.8M+15468.1%	-$2.2M-466.9%	-$390K	$0
Net income	$447.2M+1812.4%	$23.4M+84.5%	$12.7M+106.4%	-$198.3M
Basic (in dollars per share)	$3.10+1837.5%	$0.16+77.8%	$0.09+106.2%	-$1.46
Diluted (in dollars per share)	$2.77+1746.7%	$0.15+66.7%	$0.09+106.2%	-$1.46
Basic (in shares)	144.32B-0.7%	145.32B+2.4%	141.96B+104732.6%	135.4M
Diluted (in shares)	161.41B+0.7%	160.34B+8.0%	148.51B+109572.2%	135.4M
Product [Member]
License [Member]

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 11 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.